Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis

被引:0
|
作者
Shinn, Grace [1 ]
Berger, Karen [2 ]
Roh, David [3 ]
Doyle, Kevin [3 ]
Boehme, Amelia K. [3 ]
Connolly, Edward Sander [4 ]
Park, Soojin [3 ]
Agarwal, Sachin [3 ]
Claassen, Jan [3 ]
Der-Nigoghossian, Caroline [1 ,5 ]
机构
[1] Columbia Univ, NewYork Presbyterian Hosp, Dept Pharm, Irving Med Ctr, New York, NY USA
[2] Weill Cornell Med Ctr, NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA
[3] Columbia Univ, NewYork Presbyterian Hosp, Dept Neurol, Irving Med Ctr, New York, NY USA
[4] Columbia Univ, NewYork Presbyterian Hosp, Dept Neurosurg, Irving Med Ctr, New York, NY USA
[5] Columbia Irving Med Ctr, NewYork Presbyterian Hosp, Dept Pharm, 622 West 168th St, New York, NY 10032 USA
来源
NEUROHOSPITALIST | 2023年 / 13卷 / 03期
关键词
unfractionated heparin; neurocritical care; activated partial thromboplastin time; anti-factor Xa; UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; PREVENTION; THROMBOSIS; WEIGHT; VALUES; APTT; CARE;
D O I
10.1177/19418744231159917
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Laboratory monitoring is not recommended when subcutaneous unfractionated heparin (SQ-UFH) is administered at prophylactic doses. However, aPTT prolongation and associated hemorrhage has been reported in the neurocritically ill. At our institution, Neuroscience Intensive Care Unit (Neuro-ICU) patients with prolonged aPTT are further evaluated with a follow up aPTT and anti-factor Xa. Purpose The purpose of this study was to describe concordance between aPTT and anti-factor Xa in neurocritically ill patients receiving prophylactic SQ-UFH with evidence of aPTT prolongation. Methods A retrospective chart review of adult patients admitted to the Neuro-ICU from June 2017 to June 2019 was performed. Patients were included if they received SQ-UFH with aPTT levels and at least one anti-factor Xa level drawn within one hour of each other. Concordance between paired aPTT and anti-factor Xa was evaluated using Cohen's weighted kappa. Results Forty two patients with 56 paired aPTT and anti-factor Xa levels were included. The most prescribed SQ-UFH regimen was 5000 units every 8 hours (60.7%) and anti-factor Xa levels were drawn a median (IQR) of 5.7 (3.1-10.7) hours after the SQ-UFH dose. Only 16 (28.6%) pairs were in concordance. The analysis showed a weighted kappa of .09; 95% CI [-.05 to .22] indicating poor agreement. Conclusions In neurocritically ill patients receiving prophylactic SQ-UFH with aPTT prolongation, there was poor concordance between aPTT and anti-factor Xa. This suggests that aPTT prolongation may not be solely driven by heparin activity and further evaluation of mechanistic drivers for coagulopathy in this population is necessary.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [32] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time: reply to a rebuttal
    Cuker, A.
    Cines, D. B.
    Pollak, E. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (12) : 2158 - 2159
  • [33] Anti-factor Xa Levels Versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin in Patients with Continuous Flow Left Ventricular Assist Devices
    Yarmohammadi, H.
    Holley, C.
    Thennapin, T.
    Duval, S.
    Pritzker, M.
    Cogswell, R.
    John, R.
    Colvin-Adams, M.
    Eckman, P.
    Adatya, S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S23 - S24
  • [34] Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
    Monteagudo-Vela, Maria
    Bowles, Christopher
    Raj, Binu
    Robinson, Derek
    Simon, Andre
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (02) : 322 - 325
  • [35] Concordance of the activated partial thromboplastin time and the anti-activated factor X assay in monitoring unfractionated heparin therapy in critically ill patients
    Rettmann, JA
    Markowitz, BA
    Wilson, L
    Mayer, J
    Lehman, CM
    CHEST, 2004, 126 (04) : 875S - 876S
  • [36] Comparison of Activated Partial Thromboplastin Time (aPTT) and Anti-Factor Xa for Low Intensity Unfractionated Heparin Monitoring in Patients with Mechanical Circulatory Support Devices (MCSD)
    Volod, O.
    Lam, L. D.
    Barglowski, M.
    Mirocha, J.
    Runyan, C.
    Moriguchi, J.
    Czer, L. S.
    Arabia, F.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S443 - S443
  • [37] Components of variability of activated partial thromboplastin time (APTT) vs. anti-factor Xa (AXa) on unfractionated heparin (UFH) dose adjustments
    Guerrero, F.
    Faure, A.
    Diemert, V
    Voisin, S.
    Sie, P.
    Riviere, Bura A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 683 - 684
  • [38] CASE CONTROL STUDY OF THE PERFORMANCE OF ACTIVATED PARTIAL THROMBOPLASTIN TIME VERSUS ANTI-FACTOR XA ACTIVITY FOR THE MONITORING OF THERAPEUTIC UNFRACTIONATED HEPARIN IN PEDIATRICS
    Trucco, Matteo
    Lehmann, Christoph
    Mollenkopf, Nicole
    Takemoto, Cliff
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S32 - S32
  • [39] IMPROVING CLINICAL DECISION MAKING FOR HEPARINIZED PATIENTS WITH DISCORDANT ANTI-FACTOR XA ACTIVITY AND ACTIVATED PARTIAL THROMBOPLASTIN TIME.
    Gombar, Saurabh
    Krishnan, Anandi
    Zehnder, James
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 : 40 - 40
  • [40] Anti-Factor Xa Assay Is a Superior Correlate of Heparin Dose Than Activated Partial Thromboplastin Time or Activated Clotting Time in Pediatric Extracorporeal Membrane Oxygenation
    Liveris, Anna
    Bello, Ricardo A.
    Friedmann, Patricia
    Duffy, Melissa A.
    Manwani, Deepa
    Killinger, James S.
    Rodriquez, Daniel
    Weinstein, Samuel
    PEDIATRIC CRITICAL CARE MEDICINE, 2014, 15 (02) : E72 - E79